Stock Analysts

Can Southern Company (SO) Keep its Earnings Streak Alive?

Southern Company ( SO ) is set to release fourth-quarter 2014 financial results before the opening bell on Feb 4, 2015. The electric utility firm's earnings have surpassed the Zacks Consensus Estimate in each of the trailing four quarters and has an average positive surprise of 6.93%. Let’s see how things are shaping up for this announcement. […]

Kitco Video

How Does Holmes See Gold After Super Bowl Sunday?

[youtube NUD8uEJ_Tjo] Kitco News speaks with US Global’s Frank Holmes to see how he sees gold set up following Sunday’s Super Bowl XLIX. Holmes says when looking at gold as a currency, it has performed “exceptionally well” however, he does think gold stocks are in need of a reversal. “Statistically speaking, gold stocks are so depressed,” he says […]

Upgrades

RYERSON HOLDING (RYI) Upgraded by Zacks to NEUTRAL

Zacks Investment Research upgraded shares of RYERSON HOLDING (RYI) from UNDERPERFORM to NEUTRAL on February 02, 2015, with a target price of $6.50. Ryerson Holding Corporation is a services company that processes and distributes metals. The Company, through its subsidiaries, purchases, processes, and distributes various forms of stainless steel, aluminum, carbon, alloy steel, nickel, and red metals. […]

Mergers & Acquisitions

BABA SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Securities Fraud Violations by the Board of Directors of Alibaba Group Holding Limited

BABA SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Securities Fraud Violations by the Board of Directors of Alibaba Group Holding Limited PR Newswire NEW YORK, Feb. 2, 2015 NEW YORK , Feb. 2, 2015 /PRNewswire/ — Levi & Korsinsky, LLP is investigating Alibaba Group Holding Limited (NYSE: BABA) in connection with possible violations of federal securities laws by the Board of Directors of the Company. […]

Downgrades

TELEDYNE TECH (TDY) Downgraded by Zacks to NEUTRAL

Zacks Investment Research downgraded shares of TELEDYNE TECH (TDY) from OUTPERFORM to NEUTRAL on February 02, 2015, with a target price of $112.10. Teledyne Technologies Inc. is a leading provider of sophisticated electronic and communication products, systems engineering solutions and information technology services, and aerospace engines and components. […]

Downgrades

VTTI EGY PTNRS (VTTI) Downgraded by Zacks to NEUTRAL

Zacks Investment Research downgraded shares of VTTI EGY PTNRS (VTTI) from OUTPERFORM to NEUTRAL on February 02, 2015, with a target price of $26.10. VTTI Energy Partners LP owns, operates, develops and acquires refined petroleum product and crude oil terminals, and related energy infrastructure. VTTI Energy Partners LP is based in London, United Kingdom […]

Downgrades

CHINA BIOLOGIC (CBPO) Downgraded by Zacks to NEUTRAL

Zacks Investment Research downgraded shares of CHINA BIOLOGIC (CBPO) from OUTPERFORM to NEUTRAL on February 02, 2015, with a target price of $82.00. China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Company Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. […]

Downgrades

Big 5 Sporting Goods Corporation (BGFV) Downgraded by Zacks to NEUTRAL

Zacks Investment Research downgraded shares of Big 5 Sporting Goods Corporation (BGFV) from OUTPERFORM to NEUTRAL on February 02, 2015, with a target price of $13.00. Big 5 Sporting posted lower-than-expected preliminary sales results for the fourth quarter and fiscal 2014 owing to soft holiday comps, leading management to lower its earnings per share guidance for the same period. […]

Upgrades

OMEROS CORP (OMER) Upgraded by Zacks to OUTPERFORM

Zacks Investment Research upgraded shares of OMEROS CORP (OMER) from NEUTRAL to OUTPERFORM on February 02, 2015, with a target price of $25.40. Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. […]